User menu

Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.

Bibliographic reference Woillard, Jean-Baptiste ; Mourad, Michel ; Neely, Michael ; Capron, Arnaud ; van Schaik, Ron H ; et. al. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.. In: Frontiers in Pharmacology, Vol. 8, p. 358 (2017)
Permanent URL
  1. Andreu Franc, Colom Helena, Elens Laure, van Gelder Teun, van Schaik Ronald H. N., Hesselink Dennis A., Bestard Oriol, Torras Joan, Cruzado Josep M., Grinyó Josep M., Lloberas Nuria, A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach, 10.1007/s40262-016-0491-3
  2. Anglicheau D., Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients, 10.1097/01.asn.0000073901.94759.36
  3. Åsberg Anders, Midtvedt Karsten, van Guilder Mike, Størset Elisabet, Bremer Sara, Bergan Stein, Jelliffe Roger, Hartmann Anders, Neely Michael N., Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation, 10.1111/tri.12194
  4. Benkali Khaled, Prémaud Aurelie, Picard Nicolas, Rérolle Jean-Philippe, Toupance Olivier, Hoizey Guillaume, Turcant Alain, Villemain Florence, Le Meur Yannick, Marquet Pierre, Rousseau Annick, Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients : , 10.2165/11318080-000000000-00000
  5. Bigdeli T. Bernard, Neale Benjamin M., Neale Michael C., Statistical Properties of Single-Marker Tests for Rare Variants, 10.1017/thg.2014.17
  6. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik RHN, Thummel KE, Klein TE, Caudle KE, MacPhee IAM, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing, 10.1002/cpt.113
  7. Borobia Alberto M, Romero Ivan, Jimenez Carlos, Gil Fernando, Ramirez Elena, Gracia Raquel De, Escuin Fernando, Gonzalez Elena, Sansuán Antonio J Carcas, Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection : , 10.1097/ftd.0b013e3181a8f02a
  8. Bouamar R., Shuker N., Hesselink D. A., Weimar W., Ekberg H., Kaplan B., Bernasconi C., van Gelder T., Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials† : Tacrolimus Concentrations and Acute Rejection, 10.1111/ajt.12191
  9. Capron Arnaud, Mourad Michel, De Meyer Martine, De Pauw Luc, Eddour Djamila Chaib, Latinne Dominique, Elens Laure, Haufroid Vincent, Wallemacq Pierre, CYP3A5andABCB1polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation, 10.2217/pgs.10.43
  10. Comets Emmanuelle, Brendel Karl, Mentré France, Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R, 10.1016/j.cmpb.2007.12.002
  11. Cotreau Monette M, von Moltke Lisa L, Greenblatt David J, The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates : , 10.2165/00003088-200544010-00002
  12. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers D R, In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients, 10.1038/clpt.2012.109
  13. de Jonge H, Elens L, de Loor H, van Schaik R H, Kuypers D R J, The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients, 10.1038/tpj.2014.49
  14. de Jonge Hylke, Vanhove Thomas, de Loor Henriëtte, Verbeke Kristin, Kuypers Dirk R. J., Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit : CYP3A4 activity partially explains decline in tacrolimus clearance, 10.1111/bcp.12703
  15. de Keyser Catherine E, Becker Matthijs L, Uitterlinden André G, Hofman Albert, Lous Jan J, Elens Laure, Visser Loes E, van Schaik Ron HN, Stricker Bruno H, Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study, 10.2217/pgs.13.112
  16. De Meyer Martine, Haufroid Vincent, Kanaan Nada, Darius Tom, Buemi Antoine, De Pauw Luc, Eddour Djamila Chaïb, Wallemacq Pierre, Mourad Michel, Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study, 10.2217/pgs-2016-0005
  17. Ekberg Henrik, Tedesco-Silva Helio, Demirbas Alper, Vítko Štefan, Nashan Björn, Gürkan Alp, Margreiter Raimund, Hugo Christian, Grinyó Josep M., Frei Ulrich, Vanrenterghem Yves, Daloze Pierre, Halloran Philip F., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, 10.1056/nejmoa067411
  18. Elens L., Bouamar R., Hesselink D. A., Haufroid V., van der Heiden I. P., van Gelder T., van Schaik R. H. N., A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients, 10.1373/clinchem.2011.165613
  19. Elens Laure, Capron Arnaud, Kerckhove Valérie Van, Lerut Jan, Mourad Michel, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation : , 10.1097/fpc.0b013e3282e9a533
  20. Elens Laure, Capron Arnaud, van Schaik Ron HN, De Meyer Martine, De Pauw Luc, Eddour Djamila C., Latinne Dominique, Wallemacq Pierre, Mourad Michel, Haufroid Vincent, Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation : Toward Updated Genotype-Based Dosage Guidelines, 10.1097/ftd.0b013e318296045b
  21. Elens Laure, Hesselink Dennis A., Bouamar Rachida, Budde Klemens, de Fijter Johannes W., De Meyer Martine, Mourad Michel, Kuypers Dirk R. J., Haufroid Vincent, van Gelder Teun, van Schaik Ron H. N., Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine a in Renal Transplant Patients : , 10.1097/ftd.0b013e31829da6dd
  22. Elens Laure, Hesselink Dennis A., van Schaik Ron H. N., van Gelder Teun, TheCYP3A4*22allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations : Letter to the Editors, 10.1111/bcp.12038
  23. Elens Laure, Nieuweboer Annemieke, Clarke Stephen J, Charles Kellie A, de Graan Anne-Joy, Haufroid Vincent, Mathijssen Ron HJ, van Schaik Ron HN, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin, 10.2217/pgs.12.202
  24. Elens Laure, Nieuweboer Annemieke J.M., Clarke Stephen J., Charles Kellie A., de Graan Anne-Joy M., Haufroid Vincent, van Gelder Teun, Mathijssen Ron H.J., van Schaik Ron H.N., Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin : , 10.1097/fpc.0b013e32835dc113
  25. Elens Laure, Sombogaard Ferdi, Hesselink Dennis A., van Schaik Ron H.N., van Gelder Teun, Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus : , 10.1097/fpc.0000000000000001
  26. Elens Laure, van Gelder Teun, Hesselink Dennis A, Haufroid Vincent, van Schaik Ron HN, CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy, 10.2217/pgs.12.187
  27. Gijsen Violette MGJ, van Schaik Ron HN, Elens Laure, Soldin Offie P, Soldin Steven J, Koren Gideon, de Wildt Saskia N, CYP3A4*22andCYP3Acombined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients, 10.2217/pgs.13.80
  28. Guy-Viterbo Vanessa, Baudet Henry, Elens Laure, Haufroid Vincent, Lacaille Florence, Girard Muriel, Debray Dominique, Chardot Christophe, Reding Raymond, Wallemacq Pierre, Musuamba Flora, Influence of donor–recipientCYP3A4/5genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach, 10.2217/pgs.14.75
  29. Han Nayoung, Yun Hwi-yeol, Hong Jin-yi, Kim In-Wha, Ji Eunhee, Hong Su Hyun, Kim Yon Su, Ha Jongwon, Shin Wan Gyoon, Oh Jung Mi, Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients, 10.1007/s00228-012-1296-4
  30. Haufroid Vincent, Mourad Michel, Van Kerckhove Val??rie, Wawrzyniak Jeremie, De Meyer Martine, Eddour Djamila Chaib, Malaise Jacques, Lison Dominique, Squifflet Jean-Paul, Wallemacq Pierre, The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients : , 10.1097/00008571-200403000-00002
  31. Haufroid V., Wallemacq P., VanKerckhove V., Elens L., De Meyer M., Eddour D. C., Malaise J., Lison D., Mourad M., CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study, 10.1111/j.1600-6143.2006.01518.x
  32. Henderson Colin J., Otto Diana M. E., Carrie Dianne, Magnuson Mark A., McLaren Aileen W., Rosewell Ian, Wolf C. Roland, Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase, 10.1074/jbc.m212087200
  33. Hesselink Dennis A., Bouamar Rachida, Elens Laure, van Schaik Ron H. N., van Gelder Teun, The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation, 10.1007/s40262-013-0120-3
  34. Hesselink D, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, 10.1016/s0009-9236(03)00168-1
  35. Huang N., Agrawal V., Giacomini K. M., Miller W. L., Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, 10.1073/pnas.0711621105
  36. Jelliffe Roger, Schumitzky Alan, Van Guilder Michael, Population Pharmacokinetics/Pharmacodynamics Modeling: Parametric and Nonparametric Methods : , 10.1097/00007691-200006000-00019
  37. Kamdem L. K., Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus, 10.1373/clinchem.2005.050047
  39. Klein Kathrin, Thomas Maria, Winter Stefan, Nussler Andreas K., Niemi Mikko, Schwab Matthias, Zanger Ulrich M., PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo, 10.1038/clpt.2011.336
  40. Kuypers Dirk R.J., de Loor Henriette, Naesens Maarten, Coopmans Tamara, de Jonge Hylke, Combined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipients : , 10.1097/fpc.0000000000000095
  41. MacPhee Iain A.M., Fredericks Salim, Mohamed Maha, Moreton Michelle, Carter Nicholas D., Johnston Atholl, Goldberg Lawrence, Holt David W., Tacrolimus Pharmacogenetics: The CYP3A5*1 Allele Predicts Low Dose-Normalized Tacrolimus Blood Concentrations in Whites and South Asians : , 10.1097/
  42. Moes D. J. A. R, van der Bent S. A. S, Swen J. J., van der Straaten T., Inderson A., Olofsen E., Verspaget H. W., Guchelaar H. J., den Hartigh J., van Hoek B., Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients, 10.1007/s00228-015-1963-3
  43. Richards Katelyn R., Hager David, Muth Brenda, Astor Brad C., Kaufman Dixon, Djamali Arjang, Tacrolimus Trough Level at Discharge Predicts Acute Rejection in Moderately Sensitized Renal Transplant Recipients : , 10.1097/tp.0000000000000149
  44. Saint-Marcoux Franck, Debord Jean, Undre Nasrullah, Rousseau Annick, Marquet Pierre, Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation : , 10.1097/ftd.0b013e3181cc70db
  45. Saint-Marcoux Franck, Knoop Christiane, Debord Jean, Thiry Philippe, Rousseau Annick, Estenne Marc, Marquet Pierre, Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies : , 10.2165/00003088-200544120-00010
  46. Shi X.-J., Geng F., Jiao Z., Cui X.-Y., Qiu X.-Y., Zhong M.-K., Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis : Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the PK of tacrolimus, 10.1111/j.1365-2710.2010.01206.x
  47. Shuker N., Bouamar R., van Schaik R. H. N., Clahsen-van Groningen M. C., Damman J., Baan C. C., van de Wetering J., Rowshani A. T., Weimar W., van Gelder T., Hesselink D. A., A Randomized Controlled Trial Comparing the Efficacy ofCyp3a5Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation, 10.1111/ajt.13691
  48. Staatz C., Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation, 10.1093/ndt/16.9.1905
  49. Staatz Christine E, Tett Susan E, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation : , 10.2165/00003088-200443100-00001
  50. Størset Elisabet, Åsberg Anders, Skauby Morten, Neely Michael, Bergan Stein, Bremer Sara, Midtvedt Karsten, Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study : , 10.1097/tp.0000000000000708
  51. Størset Elisabet, Holford Nick, Midtvedt Karsten, Bremer Sara, Bergan Stein, Åsberg Anders, Importance of hematocrit for a tacrolimus target concentration strategy, 10.1007/s00228-013-1584-7
  52. Tang J.T., Andrews L.M., van Gelder T., Shi Y.Y., van Schaik R.H.N., Wang L.L., Hesselink D.A., Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, 10.1517/17425255.2016.1170808
  53. Thervet E, Loriot M A, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng A E, Subra J F, Beaune P, Legendre C, Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, 10.1038/clpt.2010.17
  54. van Gelder T, Hesselink D A, Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?, 10.1038/clpt.2010.42
  55. Wallemacq Pierre, Goffinet Jean-Sebastien, OʼMorchoe Susan, Rosiere Thomas, Maine Gregory T, Labalette Myriam, Aimo Giuseppe, Dickson Diana, Schmidt Ed, Schwinzer Reinhard, Schmid Rainer W, Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus Assay : , 10.1097/ftd.0b013e31819c6a37
  56. Werk A N, Cascorbi I, Functional Gene Variants of CYP3A4, 10.1038/clpt.2014.129
  57. Woillard Jean-Baptiste, de Winter Brenda C. M., Kamar Nassim, Marquet Pierre, Rostaing Lionel, Rousseau Annick, Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf® and once daily Advagraf® : Bayesian estimator for both Prograf® and Advagraf®, 10.1111/j.1365-2125.2010.03837.x
  58. Zhang Jing-Jing, Liu Shuai-Bing, Xue Ling, Ding Xiao-Liang, Zhang Hua, Miao Li-Yan, The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients, 10.5414/cp202152
  59. Zuo Xiao-cong, Ng Chee M., Barrett Jeffrey S., Luo Ai-jing, Zhang Bi-kui, Deng Chen-hui, Xi Lan-yan, Cheng Ke, Ming Ying-zi, Yang Guo-ping, Pei Qi, Zhu Li-jun, Yuan Hong, Liao Hai-qiang, Ding Jun-jie, Wu Di, Zhou Ya-nan, Jing Ning-ning, Huang Zhi-jun, Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients : a population pharmacokinetic analysis, 10.1097/fpc.0b013e32835fcbb6